✦ LIBER ✦

Reactogenicity and immunogenicity of rotavirus WC3 vaccine in 5-12-month old infants

✍ Scribed by Garbag-Chenon, A.; Fontaine, J.-L.; Lasfargues, G.; Clark, H.F.; Guyot, J.; Le Moing, G.; Hessel, L.; Bricout, F.

Book ID: 123354813
Publisher: Elsevier Science
Year: 1989
Tongue: English
Weight: 601 KB
Volume: 140
Category: Article
ISSN: 0923-2516
DOI: 10.1016/S0923-2516(89)80098-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of bovine rota

Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants

✍ Y. Maldonado; L. Hestvik; M. Wilson; T. Townsend; J. O'Hare; S. Wee; R. Yolken 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 411 KB

Measles vaccine immunogenicity and antib

Measles vaccine immunogenicity and antibody persistence in 12- vs. 15-month-old infants

✍ Subhash C. Arya 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 22 KB

Measles vaccine immunogenicity and antib

Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants

✍ Candice E Johnson; Anil Darbari; Deepika S Darbari; David Nalin; Judy Whitwell; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Co-Administration of a Human Rotavirus V

Co-Administration of a Human Rotavirus Vaccine Rix4414 with DTPw-HBv Vaccines: Immunogenicity and Reactogenicity in Healthy Infants

✍ V.K. Tatochenko; V.V. Romanenko; S.M. Kharit; I. Smolenov; I. LeFevre; N. De Cle 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Immunogenicity, reactogenicity and safet

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants

✍ T. Vesikari; A. Karvonen; A. Bouckenooghe; P.V. Suryakiran; I. Smolenov; H.H. Ha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 627 KB

A trial of RIT-4237 rotavirus vaccine in

A trial of RIT-4237 rotavirus vaccine in 1-month-old infants

✍ I. D. Mutz; F. Krainer; J. Deutsch; Ch. Kunz; D. E. Teuwen 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 236 KB

In a double blind placebo-controlled study rotavirus vaccine RIT 4237 was offered to young infants after the fourth week of life. The vaccine was very well tolerated. Fifty-seven out of 100 vaccine recipients and 10 out of 103 placebo recipients developed rotavirus-IgM-antibodies during the 1 month